Fiche centre
Neuromuscular Research Center
Phoenix — United States
Essais liés5clinical trials
VillePhoenixlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03532542
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04165824 | Safety Study of Oral Edaravone Administered in Subjects With ALS | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04577404 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | RECRUITING |
| M5049 dose | Myopathies | Phase 2 | NCT05650567 | Study of M5049 in DM and PM Participants (NEPTUNIA) | TERMINATED |
| Casimersen | Myopathies | Phase 3 | NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | TERMINATED |